Cargando…
Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
Venetoclax is a potent oral, highly selective small-molecule inhibitor of the antiapoptotic B-cell lymphoma 2 protein approved for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma in treatment-naive patients (in combination with obinutuzumab) or for patients with relapsed/refractory...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214960/ https://www.ncbi.nlm.nih.gov/pubmed/35755897 http://dx.doi.org/10.6004/jadpro.2022.13.4.4 |
_version_ | 1784731111686930432 |
---|---|
author | Waggoner, Matthew Katsetos, John Thomas, Emilee Galinsky, Ilene Fox, Heather |
author_facet | Waggoner, Matthew Katsetos, John Thomas, Emilee Galinsky, Ilene Fox, Heather |
author_sort | Waggoner, Matthew |
collection | PubMed |
description | Venetoclax is a potent oral, highly selective small-molecule inhibitor of the antiapoptotic B-cell lymphoma 2 protein approved for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma in treatment-naive patients (in combination with obinutuzumab) or for patients with relapsed/refractory CLL (in combination with rituximab). Venetoclax, in combination with azacitidine, decitabine, or low-dose cytarabine, is also approved in the United States for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are ≥ 75 years or have comorbidities that preclude use of intensive induction chemotherapy. Clinical studies of patients with CLL or AML report both hematologic (e.g., neutropenia) and nonhematologic (e.g., gastrointestinal disorders and tumor lysis syndrome) adverse events associated with administration of venetoclax. It is therefore essential to provide information on the appropriate management of venetoclax-associated side effects. This article discusses the efficacy and safety of venetoclax administration and presents strategies specifically for the management of neutropenia and certain nonhematologic adverse events in patients receiving venetoclax for the treatment of AML and CLL. |
format | Online Article Text |
id | pubmed-9214960 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Harborside Press LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-92149602022-06-23 Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia Waggoner, Matthew Katsetos, John Thomas, Emilee Galinsky, Ilene Fox, Heather J Adv Pract Oncol Review Venetoclax is a potent oral, highly selective small-molecule inhibitor of the antiapoptotic B-cell lymphoma 2 protein approved for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma in treatment-naive patients (in combination with obinutuzumab) or for patients with relapsed/refractory CLL (in combination with rituximab). Venetoclax, in combination with azacitidine, decitabine, or low-dose cytarabine, is also approved in the United States for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are ≥ 75 years or have comorbidities that preclude use of intensive induction chemotherapy. Clinical studies of patients with CLL or AML report both hematologic (e.g., neutropenia) and nonhematologic (e.g., gastrointestinal disorders and tumor lysis syndrome) adverse events associated with administration of venetoclax. It is therefore essential to provide information on the appropriate management of venetoclax-associated side effects. This article discusses the efficacy and safety of venetoclax administration and presents strategies specifically for the management of neutropenia and certain nonhematologic adverse events in patients receiving venetoclax for the treatment of AML and CLL. Harborside Press LLC 2022-05 2022-06-21 /pmc/articles/PMC9214960/ /pubmed/35755897 http://dx.doi.org/10.6004/jadpro.2022.13.4.4 Text en © 2022 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Waggoner, Matthew Katsetos, John Thomas, Emilee Galinsky, Ilene Fox, Heather Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia |
title | Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia |
title_full | Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia |
title_fullStr | Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia |
title_full_unstemmed | Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia |
title_short | Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia |
title_sort | practical management of the venetoclax-treated patient in chronic lymphocytic leukemia and acute myeloid leukemia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214960/ https://www.ncbi.nlm.nih.gov/pubmed/35755897 http://dx.doi.org/10.6004/jadpro.2022.13.4.4 |
work_keys_str_mv | AT waggonermatthew practicalmanagementofthevenetoclaxtreatedpatientinchroniclymphocyticleukemiaandacutemyeloidleukemia AT katsetosjohn practicalmanagementofthevenetoclaxtreatedpatientinchroniclymphocyticleukemiaandacutemyeloidleukemia AT thomasemilee practicalmanagementofthevenetoclaxtreatedpatientinchroniclymphocyticleukemiaandacutemyeloidleukemia AT galinskyilene practicalmanagementofthevenetoclaxtreatedpatientinchroniclymphocyticleukemiaandacutemyeloidleukemia AT foxheather practicalmanagementofthevenetoclaxtreatedpatientinchroniclymphocyticleukemiaandacutemyeloidleukemia |